Latest / Bloomberg Intelligence / Novo Halves Ozempic Price to $499 a Month For Those Paying Cash

Transcript

Novo Halves Ozempic Price to $499 a Month For Those Paying Cash · Bloomberg Intelligence

• 0:02
  Speaker 1: Bloomberg Audio Studios, podcasts, radio news. You're listening to the
• 0:10
  Speaker 1: Bloomberg Intelligence Podcast. Catch us live weekdays at ten am
• 0:14
  Speaker 1: Eastern on Apple Coarclay and Android Auto with the Bloomberg
• 0:17
  Speaker 1: Business App. Listen on demand wherever you get your podcasts,
• 0:21
  Speaker 1: or watch us live on YouTube.
• 0:24
  Speaker 2: We had some FDA approvals.
• 0:25
  Speaker 3: They're pushing gains in some part of pharmaceutical companies, specifically
• 0:29
  Speaker 3: Novo nor Disk. So here to break that down, and
• 0:32
  Speaker 3: a whole lot more news that's coming out about Novo
• 0:35
  Speaker 3: is Madison Miller, She's Bloomberg Health reporter. But the big
• 0:37
  Speaker 3: news so the weight loss drugg we go. We got
• 0:39
  Speaker 3: this use approval to treat a form of liver disease.
• 0:43
  Speaker 3: So what does this mean for the company.
• 0:45
  Speaker 4: Yeah, so on Friday afternoon, late on Friday, Nova artists
• 0:49
  Speaker 4: got approval for Regovi, which is its weight loss drug
• 0:52
  Speaker 4: to treat a liver disease called MASH. And this sort
• 0:55
  Speaker 4: of is a we've seen over the last couple of years.
• 0:58
  Speaker 4: So many studies come out show the potential health benefits
• 1:01
  Speaker 4: of these weight loss drugs beyond just you know, the
• 1:04
  Speaker 4: reducing the number on the scale. And we knew from
• 1:07
  Speaker 4: studies that there was some benefit to the liver from
• 1:10
  Speaker 4: taking these drugs, and so Nova was able to notch
• 1:12
  Speaker 4: and approval for that, which helps one with insurance coverage.
• 1:16
  Speaker 4: Wigov and then Eli Lilly's drug zet Bound are still
• 1:19
  Speaker 4: not super widely covered by insurance companies for weight loss,
• 1:24
  Speaker 4: but having some of these other health benefits shown and
• 1:27
  Speaker 4: proven in studies helps them convince insures that they are
• 1:30
  Speaker 4: worth covering, and so this gives them an edge against Lily.
• 1:33
  Speaker 4: Lily's drug, Zetbound is not approved yet for this indication,
• 1:37
  Speaker 4: and so it gives them sort of a leg up there,
• 1:41
  Speaker 4: and then it also gets I mean it sort of
• 1:46
  Speaker 4: is another benefit for Novo because they've been struggling over
• 1:52
  Speaker 4: the last year. Just with zet Bound sort of making
• 1:56
  Speaker 4: waves in the market and taking market share from Wagov.
• 2:00
  Speaker 4: This gives them a leg up there as well. And
• 2:03
  Speaker 4: just with the tumultuousness of the last few weeks, they
• 2:06
  Speaker 4: had a CEO ouster and a few other moving pieces.
• 2:10
  Speaker 4: So this is good news for them and we'll we'll see,
• 2:15
  Speaker 4: but it will maybe help them gain back some market share.
• 2:20
  Speaker 2: One of the issues for these weight loss drugs is
• 2:22
  Speaker 2: the cost and if you're not covered by insurance. They
• 2:24
  Speaker 2: really are expensive. So by slashing the cost of a
• 2:28
  Speaker 2: zempic in half, does a company believe that's going to
• 2:31
  Speaker 2: open up a big new vein of new customers. Maybe.
• 2:35
  Speaker 4: So it's interesting because if patients are on ozempic, they
• 2:39
  Speaker 4: are usually on it. It's you know, a type two
• 2:40
  Speaker 4: diabetes treatment and usually.
• 2:42
  Speaker 2: That's covered by diabetes. But does it have a side
• 2:46
  Speaker 2: benefit I guess of weight loss?
• 2:48
  Speaker 5: Yes?
• 2:48
  Speaker 4: So, I mean there are two different drugs, right, There's ozembic,
• 2:51
  Speaker 4: which is the diabetes drug wigov. They both use the
• 2:54
  Speaker 4: exact same active ingredient, which is semiglue tide. Wigov is
• 2:57
  Speaker 4: a higher dose version if you're on azempa gets lower doses,
• 3:01
  Speaker 4: so it's not quite as strong, but there is that
• 3:03
  Speaker 4: weight loss side effect on both drugs. Previously, Novo actually
• 3:08
  Speaker 4: did cut the cost of wigo V down to about
• 3:11
  Speaker 4: the same price five hundred dollars a month back in March,
• 3:14
  Speaker 4: and now they are doing the same for ozempic.
• 3:16
  Speaker 5: But it's interesting because the question.
• 3:18
  Speaker 4: Of whether or not this is going to expand access
• 3:21
  Speaker 4: for more patients sort of remains to be seen. Because again,
• 3:23
  Speaker 4: if you have ozempic, you usually are covered by insurance
• 3:27
  Speaker 4: for it.
• 3:28
  Speaker 3: Now something I also said, there are partnering in this article,
• 3:31
  Speaker 3: it said with good Rx to offer ozempic, we go
• 3:33
  Speaker 3: before the same price as pharmacies. But didn't Novo try
• 3:37
  Speaker 3: the partnership thing with Hymns and Hers and that didn't
• 3:39
  Speaker 3: work out so well.
• 3:40
  Speaker 4: Yeah, yeah, So Hyms was one of several partners that
• 3:43
  Speaker 4: Novo has sort of worked with over the last couple
• 3:45
  Speaker 4: of months again to really make waves and get into
• 3:49
  Speaker 4: this market or gain back market share because it's really
• 3:53
  Speaker 4: lost ground to Eli Lilly.
• 3:55
  Speaker 5: Hyms was one of the companies that they've partnered with.
• 3:57
  Speaker 4: They've partnered with a couple of other telehealth companies as
• 4:00
  Speaker 4: well as CVS to make this cash pay price more
• 4:03
  Speaker 4: widely available, but this is the first time that they're
• 4:06
  Speaker 4: dropping the price of ozempic as well. So this partnership
• 4:09
  Speaker 4: with good Rx, you know, any patient is essentially a coupon,
• 4:13
  Speaker 4: like any patient who goes to a pharmacy uses GoodRx
• 4:16
  Speaker 4: is going to be able to get this cash pay
• 4:18
  Speaker 4: price for ozempic.
• 4:19
  Speaker 2: And Wigov mentioned that the Hymns and Hers, those compound drugs,
• 4:24
  Speaker 2: how effective are they visa v the golp ones themselves,
• 4:29
  Speaker 2: because that would be a if I were like Novo Nordics,
• 4:31
  Speaker 2: I spent all this money to develop, that would be
• 4:33
  Speaker 2: a bummerp receise yes.
• 4:34
  Speaker 4: And that's a really good question actually, that question of
• 4:37
  Speaker 4: how effective are these drugs, because that's the problem is
• 4:40
  Speaker 4: we don't know. There are studies that drug makers are
• 4:44
  Speaker 4: required to do. They have to go through a length
• 4:46
  Speaker 4: the FDA approval process to prove that their medications are
• 4:49
  Speaker 4: safe and effective. Compounded drugs don't go through that same
• 4:52
  Speaker 4: approval process, so there's no actual studies showing how effective
• 4:56
  Speaker 4: those medications are.
• 4:57
  Speaker 5: And it's a little bit of a gamble.
• 4:58
  Speaker 4: I mean, we've seen losing weight on these compounded medications,
• 5:03
  Speaker 4: and we haven't seen a tremendous amount of side effects
• 5:07
  Speaker 4: that are really different from the branded medications. So the
• 5:12
  Speaker 4: problem is just more that we don't actually have a
• 5:14
  Speaker 4: lot of visibility into that compounded market and don't know
• 5:18
  Speaker 4: how those drugs stack up to the branded medications.
• 5:22
  Speaker 3: In the last thirty seconds or so we have where
• 5:24
  Speaker 3: does this all put Eli Lilly then, I mean they
• 5:26
  Speaker 3: already had the setback with the weight loss pill, So
• 5:29
  Speaker 3: so now we're hearing all this about Nova, where does
• 5:30
  Speaker 3: this put.
• 5:31
  Speaker 4: Them Yeah, yeah, I mean it's been it's interesting. Like
• 5:33
  Speaker 4: the two companies, I think last year it was just
• 5:37
  Speaker 4: they were so red hot and there was like nothing,
• 5:39
  Speaker 4: The expectations were sky high. There was really nothing that
• 5:41
  Speaker 4: seemingly could bring them down. But now we're seeing a
• 5:44
  Speaker 4: couple of stumbles and I think that that, you know,
• 5:46
  Speaker 4: shows again how high the expectations are for this market.
• 5:50
  Speaker 4: There's just no room for failure. But we'll see what
• 5:53
  Speaker 4: happens next to Lily.
• 5:55
  Speaker 2: When is the pill going to be available day? Twelve
• 5:58
  Speaker 2: months year?
• 5:59
  Speaker 4: Sometime twenty six So they said that they're planning to
• 6:01
  Speaker 4: file for afday approval by the end of the year
• 6:04
  Speaker 4: and then hopefully launch next year.
• 6:07
  Speaker 2: Stay with us more from Bloomberg Intelligence coming up after this.
• 6:12
  Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
• 6:16
  Speaker 1: weekdays at ten am Eastern on Apple, Cockplay and Android
• 6:19
  Speaker 1: Auto with the Bloomberg Business app. Listen on demand wherever
• 6:22
  Speaker 1: you get your podcasts, or watch us live on YouTube.
• 6:26
  Speaker 3: We do have some possible dealmaking news, so sources saying
• 6:29
  Speaker 3: to Mobravo when talks about human resources management software provider
• 6:33
  Speaker 3: day Force and take the company private. So what does
• 6:36
  Speaker 3: this all mean, we'll be the right person to break
• 6:38
  Speaker 3: it all down for us. It's Narage Batllities, Bloomberg Intelligence,
• 6:41
  Speaker 3: Senior software analyst, Nearaje. You're joining us from Princeton. Thanks
• 6:45
  Speaker 3: for joining. I want you to see if you can
• 6:47
  Speaker 3: talk to us about day force because I'm reading through
• 6:49
  Speaker 3: the article says shares a falling about sixty percent from
• 6:52
  Speaker 3: their twenty twenty one peak through Friday. Can you talk
• 6:55
  Speaker 3: about some of the things that this company has been
• 6:57
  Speaker 3: struggling with?
• 6:59
  Speaker 6: Yeah, Hi, Lisa, this has been even beyond a day
• 7:02
  Speaker 6: force struggling point. The HCM industry which they play in
• 7:06
  Speaker 6: the HR and payroll software that has been under pressure
• 7:10
  Speaker 6: along with application software. And just for a little bit
• 7:13
  Speaker 6: of valuation perspective, application software companies, they're in the seventeenth
• 7:19
  Speaker 6: percentile of their historical range and day forces at an
• 7:24
  Speaker 6: all time low. And this is telling because they are
• 7:29
  Speaker 6: facing a lot of deceleration on the top line. They
• 7:32
  Speaker 6: in twenty twenty one, twenty twenty two, they are at
• 7:34
  Speaker 6: twenty two percent sales growth. Now we're looking at eleven
• 7:38
  Speaker 6: percent for this year and next year, and there's a
• 7:41
  Speaker 6: lot of factors coming into play here. They have a
• 7:43
  Speaker 6: lot of competition. The customers are slowing in terms of
• 7:47
  Speaker 6: new ads as well as the upsell and cross sell
• 7:50
  Speaker 6: to existing customers.
• 7:52
  Speaker 2: So is this just the spending and in human resources
• 7:56
  Speaker 2: part of the pie. Is that slowing or is it
• 8:00
  Speaker 2: competition here? What's the problem for some of these companies.
• 8:05
  Speaker 6: Yeah, their competition push is limited. They play in the
• 8:10
  Speaker 6: larger enterprise segment, so they run into UKG or workday,
• 8:16
  Speaker 6: so it's not so much competition, but it's a little
• 8:18
  Speaker 6: bit of a macro trend. You have US labor non
• 8:22
  Speaker 6: farm payroll additions which discel Ray significantly and that's growing
• 8:27
  Speaker 6: at about a one percent pace. It averages two to
• 8:30
  Speaker 6: three percent, so we have a macro factor. Second, they
• 8:34
  Speaker 6: have a portfolio which is common to a lot of peers,
• 8:37
  Speaker 6: so there's a lot of portfolio convergence in HR software.
• 8:40
  Speaker 6: It's covering like payroll scope, account administration, workforce management, talent management,
• 8:49
  Speaker 6: learning management. So these players have all converged on the
• 8:52
  Speaker 6: same portfolio. They're trying to push that sale, but there's
• 8:55
  Speaker 6: only a limiting sale per customer that they're able to
• 8:59
  Speaker 6: translate to. For example, they're selling about thirteen dollars of
• 9:03
  Speaker 6: software per employee and it's only growing at a five
• 9:06
  Speaker 6: percent pace.
• 9:08
  Speaker 3: Now, No, Reij, were you surprised by this report, because
• 9:11
  Speaker 3: it seems like from how you were talking, I mean
• 9:12
  Speaker 3: kind of this path was leading to the way it
• 9:15
  Speaker 3: is that this report came out today.
• 9:18
  Speaker 6: Yeah. No, this didn't catch us by surprise in the
• 9:20
  Speaker 6: sense that we're expecting more consolidation. Paycheck acquired Paycore in April,
• 9:27
  Speaker 6: and that was a smaller player that targeted more small
• 9:31
  Speaker 6: SMB segments. This player, day Force, they're targeting a large
• 9:35
  Speaker 6: mid market customer, so we're not surprised the valuations are
• 9:39
  Speaker 6: quite low. The one positive factor here is eight CM
• 9:42
  Speaker 6: ranking in terms of AI disruption across app software is
• 9:47
  Speaker 6: on the lower side. Sales and marketing is on the
• 9:49
  Speaker 6: higher end. It service management is on the higher end.
• 9:52
  Speaker 6: So that may be a little bit of the appeal
• 9:54
  Speaker 6: coming from Thomas Bravo's lens where the AI agents are
• 9:58
  Speaker 6: not going to take over the app function hr software,
• 10:02
  Speaker 6: So easily stay with us.
• 10:04
  Speaker 2: More from Bloomberg Intelligence coming up after this.
• 10:08
  Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
• 10:12
  Speaker 1: weekdays at ten am Eastern on Applecarplay and Android Auto
• 10:15
  Speaker 1: with the Bloomberg Business app, listen on demand wherever you
• 10:18
  Speaker 1: get your podcasts, or watch us live on YouTube.
• 10:23
  Speaker 3: So Air Canada, right, they pulled their financial guidance through
• 10:25
  Speaker 3: a year, and thousands of Air Canada flight attendants they
• 10:28
  Speaker 3: walked out over the weekend. So what we want to
• 10:30
  Speaker 3: do is find out more behind the strikes, more behind
• 10:33
  Speaker 3: what's going on here with us to explain more as
• 10:36
  Speaker 3: francois to flow. He is US airline aerospace analyst here friends,
• 10:41
  Speaker 3: WI thanks for joining us over from the Princeton office.
• 10:43
  Speaker 3: First off, I mean this is the peak Trumble travel
• 10:46
  Speaker 3: summer season. How much of an impact is it going
• 10:49
  Speaker 3: to have for the company?
• 10:51
  Speaker 7: Yes, good morning, Yes exactly. That's the worst time that
• 10:55
  Speaker 7: it could happen. It's August, it's one of the busiest,
• 10:58
  Speaker 7: busiest months of the year. And when we look at
• 11:01
  Speaker 7: the number of consoliations during this weekend, almost eighty percent
• 11:05
  Speaker 7: of the flight and the seat we're concoled during this weekend,
• 11:08
  Speaker 7: So it's really significant. When we try to do the math,
• 11:14
  Speaker 7: we get to something around two hundred million impact revenues,
• 11:18
  Speaker 7: So that would be about three percent of the six
• 11:21
  Speaker 7: point two six point three billion all then you expected
• 11:25
  Speaker 7: for this quarter. So's it could be, it could be big.
• 11:30
  Speaker 7: And the question is how long does it take for
• 11:33
  Speaker 7: Canada to resume and get back to the full operation,
• 11:38
  Speaker 7: because it's not just the flights and the seats console
• 11:41
  Speaker 7: during the three days, but it's also our long does
• 11:45
  Speaker 7: it take to resume and return to a normal operation,
• 11:50
  Speaker 7: knowing that we are not even sure when flights and
• 11:52
  Speaker 7: attendance will go back to work. So that's the big question.
• 11:56
  Speaker 7: And then obviously the impact, the lasting impact on booking things,
• 12:00
  Speaker 7: fairs and the brain name that the struck could have
• 12:03
  Speaker 7: through the rest of the year, because when this kind
• 12:07
  Speaker 7: of event happened, you usually end up having to discount
• 12:11
  Speaker 7: a little bit first to low customer back to your flight,
• 12:16
  Speaker 7: so there is also those questions. But that's the kind
• 12:21
  Speaker 7: of amount that we see for this quarter. And I
• 12:25
  Speaker 7: just to give a little bit also of context, this
• 12:28
  Speaker 7: happens at a time where Canada is it by the
• 12:32
  Speaker 7: US trade dispute that all not only impacts the GDP,
• 12:35
  Speaker 7: but also impact the travel patterns and Air Canada was
• 12:40
  Speaker 7: definitely facing big headings because of this and had to
• 12:45
  Speaker 7: relocate seats from the US to somewhere else, and that
• 12:51
  Speaker 7: had an additional impact on yells during two Q and
• 12:54
  Speaker 7: likely three.
• 12:54
  Speaker 2: Q Air Canada. What's the market how's the market share
• 12:57
  Speaker 2: shakeout in Canada?
• 13:00
  Speaker 7: Or in Canada they have almost fifty percent of the
• 13:04
  Speaker 7: market in terms of capacity, between forty five and fifty
• 13:07
  Speaker 7: depending on the market, depending on the quarter, but it's
• 13:10
  Speaker 7: very significant. And then you have a second competitor, west Jet,
• 13:15
  Speaker 7: which is about thirty percent. So you have a very
• 13:18
  Speaker 7: too strong airlines in Canada that have a sizeable share.
• 13:24
  Speaker 2: All right, friend, So what Canadians this winter when it
• 13:27
  Speaker 2: gets cold? You're telling me they're not going to fly
• 13:29
  Speaker 2: down to Arizona and Florida.
• 13:32
  Speaker 6: Probably less.
• 13:34
  Speaker 7: At least Air Canada cut travel to the US. They
• 13:39
  Speaker 7: cut eight percent into Q. They were likely to do
• 13:43
  Speaker 7: the same through the end of the year. That's the
• 13:46
  Speaker 7: only way in order to make sure that yield remain
• 13:51
  Speaker 7: kind of stable. They manage this in two Q. The
• 13:54
  Speaker 7: UPE was to do it again in three Q and
• 13:57
  Speaker 7: four Q. Will see if that can happen. We see
• 14:01
  Speaker 7: what kind of fright attendance can get during the negotiation,
• 14:06
  Speaker 7: because it's also some things that the market could be
• 14:09
  Speaker 7: looking at.
• 14:10
  Speaker 2: Stay with us. More from Bloomberg Intelligence coming up after this.
• 14:15
  Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
• 14:19
  Speaker 1: weekdays at ten am Eastern on Apple Coarclay and Android
• 14:22
  Speaker 1: Auto with the Bloomberg Business App. Listen on demand wherever
• 14:25
  Speaker 1: you get your podcasts, or watch us live on YouTube.
• 14:29
  Speaker 2: Let's switch to tech. Like when I go to vacation,
• 14:32
  Speaker 2: I go to like the Jersey shore Man Deep sing, No,
• 14:35
  Speaker 2: the dude picks Calgary, like in Canada, Like, who does that?
• 14:40
  Speaker 2: I mean? I love skiing out there, so I don't.
• 14:43
  Speaker 2: Maybe he knows something we've done. It's beautiful out there.
• 14:44
  Speaker 2: I get it, Man Deep, sing, Bloomberg Intelligence Senior tech analyst,
• 14:49
  Speaker 2: Man Deep. Here's the story I want to get to.
• 14:52
  Speaker 2: Back in my day, if you were in a public
• 14:54
  Speaker 2: startup company and your stock was all tied up in
• 14:57
  Speaker 2: a private company, you had to wait for an IPO,
• 15:00
  Speaker 2: then you had to wait for the six month lockup,
• 15:02
  Speaker 2: then you could begin starting selling. That's not the case today.
• 15:04
  Speaker 2: The people open AI. There's something about six billion dollars
• 15:08
  Speaker 2: in stock here. This is becoming more and more common,
• 15:10
  Speaker 2: isn't for your tech companies?
• 15:13
  Speaker 8: It is, and I think Meta exacerbated that trend by
• 15:17
  Speaker 8: you know, the aquihiers. They've made in the last two
• 15:21
  Speaker 8: three months. I mean, there are startups that have just
• 15:24
  Speaker 8: disappeared without an outright acquisition because Meta acquired their top
• 15:30
  Speaker 8: five people or top ten people. And look, when you
• 15:33
  Speaker 8: have that sort of risk of losing talent, you got
• 15:37
  Speaker 8: to find ways to, you know, liquidate your stuff, the
• 15:42
  Speaker 8: stock that you have in your company. And for open Ai,
• 15:44
  Speaker 8: I mean, talent is paramount. This is a company that
• 15:47
  Speaker 8: may end up doing, you know, almost a twenty billion
• 15:51
  Speaker 8: dollar revenue run rate by the end of this year,
• 15:54
  Speaker 8: and the same thing for Entropic Andthropics started off the
• 15:58
  Speaker 8: year at a billion dollar round right now at a
• 16:00
  Speaker 8: five billion dollars round rate. When you five x your
• 16:03
  Speaker 8: revenue like that, you have to find ways to, you know,
• 16:07
  Speaker 8: keep your employees happy and retain them. And I think
• 16:12
  Speaker 8: this is their way of making sure the employees can
• 16:15
  Speaker 8: liquidate some of their stuff.
• 16:16
  Speaker 3: So is this a perk for all open ai employees?
• 16:20
  Speaker 3: I mean, do you have to be there a certain
• 16:21
  Speaker 3: amount of time or can anyone take part in this?
• 16:24
  Speaker 8: I mean, we don't know that level of detail, but
• 16:28
  Speaker 8: suffice to say, I think they've allocated a certain amount
• 16:33
  Speaker 8: and the private valuation of this company has gone from
• 16:37
  Speaker 8: almost two hundred and fifty to three hundred billion dollars
• 16:40
  Speaker 8: to five hundred billion dollars now, and so clearly there
• 16:45
  Speaker 8: is a lot of appetite for a company like open Ai,
• 16:48
  Speaker 8: which is at the frontier of everything that's going on
• 16:52
  Speaker 8: in generative AI, and you know there are buyers of
• 16:56
  Speaker 8: that kind of stuff.
• 16:57
  Speaker 2: I got to satisfy the banker gene in me. Is
• 17:00
  Speaker 2: there an open Ai IPO at some point?
• 17:04
  Speaker 8: Probably they will. And my hunch is, you know, when
• 17:08
  Speaker 8: you are a category leader in any sort of technology trend,
• 17:16
  Speaker 8: you want to be a public company because one, it
• 17:19
  Speaker 8: clearly helps you get more you know, long term investors
• 17:24
  Speaker 8: for your stock. And also it's it's great pr So
• 17:28
  Speaker 8: I can't imagine, you know, uh an open ai stay
• 17:33
  Speaker 8: private for very long. But that being said, you know,
• 17:37
  Speaker 8: their financials don't look great. I mean, from what we know,
• 17:41
  Speaker 8: they're burning a lot of cash right now, so it's
• 17:45
  Speaker 8: not a very profitable business model. But the top line
• 17:47
  Speaker 8: growth is really what is getting them all the attention
• 17:52
  Speaker 8: right now, so they will have to clean up that
• 17:55
  Speaker 8: op X side if they plan to go public. So
• 17:58
  Speaker 8: I don't think it's imminent in the near term, but
• 18:01
  Speaker 8: I would be surprised if it happens in the next
• 18:04
  Speaker 8: two years.
• 18:04
  Speaker 3: Hey, manap in the last minute we have here left.
• 18:06
  Speaker 3: Does this put you know, open ai as the world's
• 18:09
  Speaker 3: most valuable startup? I mean, does it push it past SpaceX?
• 18:13
  Speaker 3: Is it sustainable.
• 18:15
  Speaker 2: By far?
• 18:16
  Speaker 8: And look the top line growth. As I said, both
• 18:19
  Speaker 8: for open Ai and Tropic, this is not something we
• 18:22
  Speaker 8: see very often. So at their revenue base. I mean,
• 18:26
  Speaker 8: they are clearly the most coveted and the most talked
• 18:30
  Speaker 8: about name, and that's going to be the case for
• 18:33
  Speaker 8: a while.
• 18:34
  Speaker 2: Man, deep, what skill is the AI skill?
• 18:37
  Speaker 6: Like?
• 18:37
  Speaker 2: What are these people acquiring in these acquahiers? When are
• 18:40
  Speaker 2: pants as big packages? What's the is it coding? Is
• 18:42
  Speaker 2: it just engineering? Five oh five?
• 18:44
  Speaker 6: What is it?
• 18:46
  Speaker 4: So?
• 18:47
  Speaker 8: Right now, when you think about how GPT four and
• 18:50
  Speaker 8: five became smarter and smarter, it's about, you know, engineers
• 18:54
  Speaker 8: who can help these models become smarter and smarter in
• 18:58
  Speaker 8: terms of answering more questions. Is doing more types of
• 19:01
  Speaker 8: things and that requires a certain knowledge of probability, statistics,
• 19:06
  Speaker 8: tokenization that you know, the way large anglig models are built.
• 19:11
  Speaker 8: There is a neural net aspect to it, and that
• 19:14
  Speaker 8: refinement of LLM is what is making them more intelligent?
• 19:18
  Speaker 8: So you need to have that basic level understanding of
• 19:21
  Speaker 8: tokenization and what are the tokens that makes these LLM
• 19:26
  Speaker 8: smarter and smarter? And I think that's why they deserve
• 19:30
  Speaker 8: to get all that at tension.
• 19:33
  Speaker 1: This is the Bloomberg Intelligence Podcast, available on Apple, Spotify,
• 19:37
  Speaker 1: and anywhere else you get your podcasts. Listen live each
• 19:41
  Speaker 1: weekday ten am to noon Eastern on Bloomberg dot com,
• 19:45
  Speaker 1: the iHeartRadio app, tune In, and the Bloomberg Business app.
• 19:49
  Speaker 1: You can also watch us live every weekday on YouTube
• 19:52
  Speaker 1: and always on the Bloomberg terminal